Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Invested Capital (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Invested Capital for 15 consecutive years, with $13.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 44.77% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Sep 2025, down 44.77%, and an annual FY2024 reading of $12.3 million, down 32.89% over the prior year.
  • Invested Capital was $13.7 million for Q3 2025 at Fennec Pharmaceuticals, up from $10.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $33.0 million in Q1 2024 and bottomed at $2.8 million in Q3 2022.
  • Average Invested Capital over 5 years is $18.1 million, with a median of $16.5 million recorded in 2023.
  • The sharpest move saw Invested Capital tumbled 88.33% in 2022, then surged 416.38% in 2023.
  • Year by year, Invested Capital stood at $24.0 million in 2021, then decreased by 6.59% to $22.4 million in 2022, then dropped by 18.07% to $18.4 million in 2023, then crashed by 32.89% to $12.3 million in 2024, then rose by 11.19% to $13.7 million in 2025.
  • Business Quant data shows Invested Capital for FENC at $13.7 million in Q3 2025, $10.7 million in Q2 2025, and $12.3 million in Q1 2025.